<DOC>
	<DOCNO>NCT02961101</DOCNO>
	<brief_summary>The purpose study assess feasibility , safety , efficacy anti-PD-1 antibody combination low-dose decitabine patient relapse refractory malignancy , include Non-Hodgkin'lymphoma , anti-PD-1-resistant Hodgkin'lymphoma , gastrointestinal cancer , hepatocellular carcinoma , breast cancer , ovarian cancer lung cancer renal-cell cancer pancreatic cancer bile duct cancer .</brief_summary>
	<brief_title>Anti-PD-1 Antibody Combination With Low-dose Decitabine Relapsed Refractory Malignancies</brief_title>
	<detailed_description>Primary objective : To assess feasibility safety Anti-PD-1 antibody combination decitabine administer every 3 week subject relapse refractory malignancy . Secondary objective : 1 ) To assess antitumor activity Anti-PD-1 antibody combination decitabine subject relapse refractory malignancy . 2 ) To characterize immunological effect Anti-PD-1 antibody combination decitabine . 3 ) To characterize immunological effect Anti-PD-1 antibody combination decitabine . Exploratory objective : 1 ) To analysis potential biological parameter correlate clinical response toxicity . 2 ) To search predictive biomarkers guide choose patient undergo treatment Anti-PD-1 antibody combination decitabine . Safety Evaluation : Adverse event assess continuously study 100 day post last treatment , evaluate accord NCI CTCAE Version 4.0 . Efficacy Evaluation : 1 ) Treatment response lymphoma define use International Workshop Standardize Response Criteria non-Hodgkin 's Lymphomas ; 2 ) Treatment response solid tumor define use Response Evaluation Criteria Solid Tumors ( RECIST1.1 ) . evaluation index : BOR ; ORR ; PFS OS .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Subjects must histological confirmation relapse refractory malignancy , include NonHodgkin'lymphoma , antiPD1resistant Hodgkin'lymphoma , gastrointestinal cancer , hepatocellular carcinoma , breast cancer , ovarian cancer lung cancer renalcell cancer pancreatic cancer bile duct cancer . 2 . 12 80 year age . 3 . ECOG performance less 2 . 4 . Life expectancy least 3 month . 5 . Subjects lymphoma must least one measureable lesion &gt; 1 cm define lymphoma response criterion ; solid tumor must least one measureable lesion &gt; 1 cm per RECIST1.1 . 6 . Subjects must receive least two prior chemotherapy regimen , must therapy least 4 week prior Day 1 . Subjects autologous hematopoietic stemcell transplantation eligible must 3 month . 7 . Subjects must adequate bone marrow , live , renal , lung heart function . 1 . Absolute neutrophil count great equal 1,000/μL . 2 . Platelet count great equal 70,000/µL . 3 . Serum bilirubin level less equal 1.5 x upper limit normal ( ULN ) . 4 . Serum creatinine less equal 1.5 x ULN . 5 . Alanine aminotransferase [ ALT SGPT ] aspartate aminotransferase [ AST SGOT ] less equal 2.5 x ULN . 1 . Subjects autoimmune disease history syndrome require corticosteroid immunosuppressive medication . 2 . Serious uncontrolled medical disorder active infection , pulmonary intestinal infection especially . 3 . Active alimentary tract hemorrhage history alimentary tract hemorrhage 1 month . 4 . Prior organ allograft . 5 . Women pregnant breastfeeding . 6 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>relapse refractory</keyword>
	<keyword>malignancy</keyword>
	<keyword>decitabine</keyword>
	<keyword>anti-PD-1 antibody</keyword>
</DOC>